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ABSTRACT 
Chronic hepatitis B (CHB) is one of the major etiological causes of liver failure, 
cirrhosis, and hepatocellular carcinoma worldwide, and it cannot be completely cured by 
currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently 
closed circular DNA (cccDNA), the bona fide transcription template for  HBV RNAs, in the 
infected hepatocytes. Since quantifying cccDNA per se requires an invasive procedure, 
serum biomarkers reflecting the intrahepatic cccDNA activity are warranted. Recently, a 
growing body of research suggests that the circulating HBV RNA may serve as a new serum 
biomarker for HBV infection, treatment and prognosis. In order to delineate the molecular and 
clinical characteristics of serum HBV RNA, we systematically reviewed the available literature 
on serum HBV RNA dating back to early 1990s. In this review, we will summarize the reported 
serum HBV RNA quantification methods and discuss the potential HBV RNA species in 
patient serum, and compare the reported correlations of serum HBV RNA with other 
serological markers, including HBV DNA, hepatitis B surface antigen (HBsAg), e antigen 
(HBeAg), and core-related antigen (HBcrAg), as well as their correlations with the 
intrahepatic cccDNA, to assess its potential in clinical applications. The future directions for 
serum HBV RNA research will also be discussed. 
1. INTRODUCTION 
Currently, nucleos(t)ide analogues (NAs) and peginterferon are being used to treat 
patients with chronic hepatitis B (CHB), leading to suppression of HBV replication, improved 
histology, reversed histologic cirrhosis and reduced risk of hepatocellular carcinoma (HCC) 
(1). However, HBV infection cannot be completely eliminated due to the persistence of 
cccDNA in the nuclei of infected hepatocytes (2). Due to the invasive nature of liver biopsy, it 
is impractical to quantify intrahepatic cccDNA as a routine diagnosis, making it necessary to 
develop noninvasive surrogate markers to monitor the quantity or activity of cccDNA. In the 
past, several serological markers, including HBV DNA, hepatitis B surface antigen (HBsAg) 
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and hepatitis B core-related antigens (HBcrAgs), have been shown to correlate with 
intrahepatic cccDNA (3-5). Recently, serum HBV RNA has been considered as a new 
biomarker for cccDNA (6), especially in virally suppressed patients with low detectable HBV 
DNA under NA therapy. In this review, we will discuss the importance and scope of using 
serum HBV RNA as a potential biomarker for hepatitis B infection.  
 
2. SERUM HBV RNA IN VIRAL LIFE CYCLE 
As shown in Figure 1, HBV life cycle starts with the engagement of virion particles to 
the hepatocyte receptor，termed sodium taurocholate cotransporting polypeptide (NTCP), 
and then the release of nucleocapsid containing viral relaxed circular DNA (rcDNA) into 
hepatocytes. rcDNA is then transported to the nucleus, where it is converted into an 
episomal, nucleosome-decorated cccDNA minichromosome, through a series of mechanisms 
not yet fully understood (7). The cccDNA serves as a transcription template for all viral 
transcripts, including the 3.5kb precore mRNA (pcRNA) and pregenomic RNA (pgRNA), the 
2.4kb and 2.1kb surface mRNAs, and a 0.7kb X mRNA(8). The pgRNA is the template for 
both reverse transcription and translation of viral polymerase (pol) and core proteins (9). The 
pol binds to the 5’-epsilon (ε) region of pgRNA, and together they are incorporated into the 
viral capsid (10). Inside the capsid, the pol converts pgRNA into rcDNA through reverse 
transcription, followed by envelopment by HBV envelope proteins on the endoplasmic 
reticulum (ER) membrane for virion secretion through multivesicular bodies (MVBs) (11), or 
re-entry into the nucleus to replenish the cccDNA pool. In addition to rcDNA, HBV reverse 
transcription produces a minor viral DNA species, the double-stranded linear DNA (dslDNA), 
which can be secreted as virion DNA and redirected into the nucleus to form cccDNA (12). 
However, dslDNA is often randomly integrated into host genome through non-homologous 
end joining (NHEJ) (13), which may promote HCC development by inducing chromosomal 
instability, insertional mutagenesis of HBV genes and HCC-associated host genes (14). 
Unlike cccDNA, the integrated HBV genome does not produce functional pgRNA for viral 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
DNA replication, but may serve as an additional source for surface mRNA transcription and 
HBsAg expression (15). 
 
 According to the dogma of HBV life cycle, only the mature, DNA-containing 
nucleocapsid interacts with viral surface proteins to undergo envelopment and virion 
secretion from hepatocytes (16). Nonetheless, a large amount of HBV genome-free (“empty”) 
virions have been found in patient blood and HBV cell culture fluid (17) (Figure 1), and Ning et 
al. have coined a "Single Strand Blocking" model to explain such selective HBV 
morphogenesis whereby the single-stranded nucleic acids (ssRNA or ssDNA) within the viral 
capsids prevent HBV envelopment (18). However, this model does not apply to several 
exceptions, such as the ssDNA-containing virion of snow goose hepatitis B virus (SGHBV) 
(19), and the circulating HBV pgRNA-containing virus particles found in patient blood (6, 20). 
Theoretically, serum HBV RNA comes from the infected hepatocytes. Wang et al. 
deep-sequenced HBV RNA in serum and the corresponding regions of paired viral RNA in 
the liver, and found that the complexity and mean genetic distance between quasispecies of 
the two were comparable (21). However, the mechanism underlying the release of HBV RNA 
into circulation from infected hepatocytes remains unclear. Previous studies have 
demonstrated that HBV cell cultures noncytolytically secrete a large amount of nonenveloped 
(“naked”) capsids which contain all types of HBV DNA replicative intermediates including 
pgRNA (22), it is thus unclear whether the detected serum HBV RNA, or at least part of them, 
are from the “naked” capsid released into the blood stream from HBV infected hepatocytes in 
vivo or in vitro (6). 
 
 If the pgRNA-containing virions do exist, it is interesting to know whether they are 
infectious and could establish a new round of infection. Wang et al. reported that HBV RNA 
virion-like particles produced by NA treatment are infection-deficient (23). However, because 
NA-treated pgRNA-virion is a dead-end due to the irreversible chain termination effect of NA, 
the above study does not rule out the potential infectivity of untreated pgRNA-virion. Due to 
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the similar protein composition and density between pgRNA- and DNA-virions, it is technically 
challenging to purify pgRNA virions for infectivity test in cell cultures. Therefore, it remains 
debatable to incorporate HBV RNA virion-like particles into the canonical HBV replication 
cycle (24). It is well known that the encapsidated pgRNA is converted into rcDNA through 
reverse transcription, enveloped by viral surface proteins and secreted into the peripheral 
blood as Dane particles (25). However, it is possible that a certain amount of 
pgRNA-containing capsids may prematurely acquire envelope and get released into the 
peripheral blood (24). On the other hand, the secretion of immature pgRNA-virions and 
“naked” capsids may represent a host defense mechanism to combat with HBV infection. 
Hence, further investigation is needed to accurately portray the biogenesis and function of 
HBV RNA virion-like particles in chronic HBV infection. 
 
3. SERUM HBV RNA SPECIES AND MEASUREMENT  
HBV is known as a blood-borne, enveloped, double-stranded DNA virus. In 1996, 
Kock et al., for the first time, detected the polyadenylated HBV RNA in the serum of CHB 
patients by using rapid amplification of complementary DNA (cDNA)-ends (RACE) (26). After 
extracting HBV RNA from patient serum, a special primer consisting of an oligo(dT) stretch 
and a unique artificial anchored sequence was used to generate cDNA. The cDNA was PCR 
amplified with the upstream HBV-specific primer and downstream primers identical to the 
anchored sequence, thereby ensuring a high specificity for HBV polyA RNA amplification 
(27). Thereafter, similar method was used to detect serum HBV RNA in patients with 
HBV-related glomerulonephritis or CHB with or without successful treatment (28-30). 
RACE-based real-time quantitative PCR (RACE-qPCR) using specific primers designed for 
reverse transcription according to Kairat et al. (31), was later developed to selectively 
quantify serum 3’ full-length polyadenylated HBV RNA (flRNA) and 3’ internally truncated 
polyadenylated HBV RNA (trRNA). The RACE-qPCR-based flRNA quantification was widely 
employed in recent studies (32-35). In addition to RACE-qPCR, regular RT-qPCR methods 
with HBV-specific primers targeting X, C, or S region of HBV genome were also developed to 
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quantify serum HBV RNA (6, 20, 36-38). However, in order to avoid DNA contamination 
during RT-qPCR, DNase I treatment of the nucleic acids extracted from serum is required. 
Alternatively, quantification of serum HBV RNA  has been conducted through total HBV 
nucleic acid measurement by one step real-time RT-qPCR without removing HBV DNA by 
DNase digestion, followed by subtracting HBV DNA copy numbers determined by qPCR 
(39-41). QuantiGene assay developed by Lam et al. uses HBV-specific probes, designed to 
hybridize with the X ORF, to enable a direct quantification of RNA without cDNA synthesis or 
PCR amplification (42). Recently, Butler et al. developed an automated high-throughput 
assay to quantify serum HBV RNA, which HBV RNA was isolated using RNA selective 
extraction chemistry (Abbott mSample Preparation System), followed by a multiplex 
RT-qPCR procedure for detecting amplicons of HBV X and core region on the m2000 
platform(Abbott Molecular) (43). To further evaluate the automated prototype assay 
performance, they conducted a comparative testing of flRNA and found a good correlation 
between these two methods. All the published methods for quantifying serum HBV RNA are 
summarized in Table 1 and Figure 2 for comparison. 
 
In earlier studies, the species and existence form of serum HBV RNA have not been 
rigorously characterized. Rokuhara et al. speculated that the serum HBV RNA is incorporated 
into viral particles, but did not specify what kind of particles harbor HBV RNA (36). In 2015, 
Jansen et al. reported that HBV RNA is present in virions in CHB patients’ plasma by 
immunoprecipitating HBcAg with anti-core antibodies after treatment with Nonidet P-40 and 
dithiothreitol, however, they failed to detect HBV RNA after HBsAg immunoprecipitation (20). 
In 2016, Wang et al. conducted a series of experiments in HBV stable cell line HepAD38 and 
claimed that the supernatant HBV RNA is encapsidated pgRNA (6). However, as mentioned 
above, their study did not distinguish virions from “naked” capsids, both of which may contain 
pgRNA. Interestingly, “naked” capsids are commonly detected in supernatant of HBV cell 
cultures but are barely detected in blood of CHB patients (44, 45), indicating a possible 
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presence of RNA-virion in patient sera. Therefore, more reliable assays and convincing 
evidence are needed to verify the existence of enveloped RNA-containing HBV particles. 
 
As mentioned above, HBV produces the 3.5kb pcRNA and pgRNA, 2.4/2.1kb surface 
mRNAs, and 0.7kb X mRNA intracellularly, which share the same 3’-termimal sequences 
overlapping with X mRNA (Figures 1-2). In order to determine the serum HBV RNA species, 
Wang et al. conducted RT-qPCR assays to quantify serum total HBV RNA and 3.5kb RNA 
separately and obtained similar copy numbers. They further conducted PCR with 3.5kb HBV 
RNA-specific primers and pcRNA-specific primers and ruled out the presence of pcRNA in 
serum (6). However, Prakash et al. performed super-sensitive droplet digital PCR (ddPCR) 
with similar primers as used by Wang et al. and detected a small amount of pcRNA in serum 
(38). Nonetheless, although the discrepancy among different studies might be due to the 
variable specificity and/or sensitivity of different assays, it seems that the detected serum 
HBV RNA sequences are predominantly derived from pgRNA, Then, a critical question that 
needs to be answered is whether the serum pgRNA is 3.5kb genome-length or not. Prakash 
et al. reported that serum HBV RNA is polyadenylated and of genomic length (38), however, 
the multiple-round PCR method used in their study might have selectively amplified the 
genome-length polyadenylated pgRNA but neglected the presence of polyA-free serum HBV 
RNA , which has been identified by Hacker et al. (30). Furthermore, Lam et al. detected both 
full-length HBV pgRNA (minor species) and the spliced variants (major species) in the 
supernatant of HBV-infected HepaRG cells treated with or without lamivudine, as well as in 
CHB patient sera (42). Another study by Wang et al. reported that numerous short pgRNA 
species were detected by PCR and identified as pgRNA splicing variants and/or 3’-terminal 
truncations induced by NA treatment (23). The NA-induced accumulation of 3’-truncated 
polyA-free pgRNA, catalyzed by the RNase H activity of HBV polymerase, have also been 
demonstrated intracellularly before (46). Therefore, serum HBV RNA is likely a mixture of 
intact, spliced, and polyA-free pgRNA. Among polyadenylated serum HBV RNA species, the 
previously reported flRNA and trRNA species can be discriminated by aforementioned 
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3’-RACE-qPCR with specific RT-primers (32). The flRNA refers to HBV transcripts 
terminating at the canonical polyadenylation signal TATAAA, which is downstream of the HBx 
ORF (29, 30, 32, 47-49). A trRNA species, first identified by Hilger et al. in paired liver tumor 
tissue and peritumor tissues in 1991, it terminates at a cryptic polyadenylation signal within 
the HBx ORF (49). This signal, a CATAAA motif, is present in most HBV DNA integrants 
without the canonical polyadenylation signal (47), which may be used to polyadenylate the 
surface mRNA or HBx mRNA transcribed from the integrated HBV DNA. Thus, whether the 
encapsulated, polyadenylated serum HBV RNA is equal to flRNA or contains such trRNA 
species awaits further investigations. Collectively, the available data suggest that the species 
of serum HBV RNA are heterogeneous and the compositions of these RNA species may vary 
depending on different stages of chronic HBV infection and different antiviral treatments, and 
more importantly, the detection methods with different primers (Figure 2, Table 1). 
 
Therefore, considering that the molecular characteristics of serum HBV RNA has not 
been well defined and a standardized method for serum HBV RNA detection is unavailable, 
further basic research and assays, such as Northern blot and single-molecule direct RNA 
sequencing, are needed to achieve a better understanding of the molecular biology of serum 
HBV RNA, which will aid the development of an accurate and reliable serum HBV RNA 
measurement method.  
 
4. CORRELATION BETWEEN SERUM HBV RNA AND OTHER HBV MARKERS 
4.1. Correlation with serum HBV DNA and HBeAg 
Theoretically, both serum HBV DNA and RNA can be useful markers for HBV cccDNA 
activity in treatment-naïve patients. However, in CHB patients under NAs therapy, HBV DNA 
is suppressed due to halted pgRNA reverse transcription, making RNA a more direct marker 
for cccDNA. Consistently, van Bommel et al.  demonstrated that the levels of both serum 
HBV flRNA and trRNA strongly correlate with serum HBV DNA before treatment, but the 
correlation becomes weaker  upon receiving NAs (32) (Table 2). For untreated patients, the 
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correlation coefficient of serum HBV pgRNA and DNA is higher in HBeAg-negative patients 
than HBeAg-positive patients (r=0.741 and r=0.532, P<0.001, respectively) (37). However, a 
different study by van Campenhout et al. reported a comparable correlation of serum HBV 
flRNA to DNA between HBeAg-positive and -negative patients (r=0.72 and r=0.78, P<0.001, 
respectively) (35). Such discrepancy may be due to the differences in the number of subjects 
and/or patient characteristics. Moreover, the serum HBV RNA quantitation methods used in 
these two studies are different (Table 1), which may have resulted in different quantification 
results as well as different correlation with serum HBV DNA. Thus, the correlation between 
serum HBV RNA and DNA in HBeAg-positive and -negative patients with or without antiviral 
treatment is contingent on further investigations.  
 
4.2. Correlation with serum HBsAg and HBcrAg 
HBsAg is a widely used serological marker for chronic HBV infection, which not only 
reflects the intrahepatic HBV activity, but predicts the efficacy of antiviral agents (50). Thus 
far, only two studies have shown that serum HBV RNA levels of on-treatment patients 
strongly correlated with HBsAg titers with a correlation coefficient around 0.7 (21, 41), but 
other studies reported much moderate correlation with a correlation coefficient around 0.4 for 
pretreatment patients (32, 35, 37) (Table 3). However, for HBeAg-negative patients, there is a 
weak or no correlation between serum HBV RNA and HBsAg (20, 35, 37). One plausible 
explanation is that the serum HBsAg in HBeAg-negative patients is largely derived from the 
integrated HBV genome, rather than cccDNA (15). 
 
In addition, HBcrAg, a mixture of HBcAg, HBeAg and the less characterized p22cr, all 
of which are predominantly cccDNA-derived, has been advocated as a potential surrogate 
marker for cccDNA activity (51). One study by Akinori et al. reported that serum HBV RNA 
levels correlate well with serum HBcrAg in patients at the start of treatment (r = 0.841, 
P<0.001) and during treatment (r = 0.777, P<0.001) (36). However, more studies are needed 
to validate and establish the correlation between serum HBV RNA and HBcrAg. 
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4.3. Correlation with cccDNA and other viral markers 
NAs therapy can reduce the serum HBV DNA down to undetectable level but does not 
directly influence the production of HBsAg and HBcrAg, or serum HBV RNA from cccDNA. In 
this regard, HBsAg, HBcrAg, and particularly the serum HBV RNA, appear to be better 
surrogate markers for cccDNA than serum HBV DNA. Huang et al. reported that serum HBV 
pgRNA weakly correlated with cccDNA in the untreated CHB patients with a correlation 
coefficient of 0.363 (P<0.001) (37), which is similar with the result from Gao et al. (r=0.25, 
P<0.01) who quantified the serum polyadenylated HBV RNA by RACE-qPCR (33). In a CHB 
natural history study, Wang et al. found a moderate overall correlation between serum 3.5Kb 
RNA and intrahepatic cccDNA (r=0.596, P<0.001) among all the recruited patients; however, 
when classifying the patients into immune tolerant, HBeAg-positive immune active, inactive 
carrier, and HBeAg-negative immune active phases, the correlation disappeared in all 
phases (52). For the patients under NAs treatment, Wang et al. found no significant 
correlation between serum HBV RNA and cccDNA copy numbers (21). In addition, Gao et al. 
reported that serum HBV polyA RNA has no correlation with intrahepatic cccDNA at 96 
weeks after NAs treatment (33). Despite there being no correlation between cccDNA and 
serum HBV pgRNA, the latter strongly correlates with intrahepatic HBV pgRNA, as well as 
with the ratio of intrahepatic HBV pgRNA to cccDNA, which reflects intrahepatic viral 
transcription activity (21). In addition to the intrahepatic viral replicative markers, serum HBV 
pgRNA also correlated with liver injury or histopathology (21, 52), which raise a question on 
whether the serum HBV RNA, or at least part of them, are released through hepatocyte 
destruction.  
 
Thus, it can be concluded that the correlation between serum HBV RNA and 
intrahepatic cccDNA is not well justified, and may differ between untreated and treated 
patients. Additionally, the correlation may vary based on different CHB stages, and even 
different detection methods for serum HBV RNA and cccDNA. Therefore, developing an 
accurate and standardized protocol for serum HBV RNA and intrahepatic cccDNA 
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quantitation are urgently needed to determine the correlation between serum HBV RNA and 
intrahepatic cccDNA.  
 
5. CLINICAL SIGNIFICANCE OF SERUM HBV RNA 
5.1. Serum HBV RNA and antiviral treatment efficacy 
A number of studies have inferred that serum HBV RNA can be a useful marker for 
monitoring the efficacy of antiviral therapy, such as NAs and interferon (IFN-α) (20, 32, 34, 
41). A study on 52 CHB patients receiving NAs therapy revealed that low serum HBV RNA 
levels at week 12 of treatment can predict the initial virological response, which is defined as 
the interval from detectable to undetectable HBV DNA level <16 weeks (41). However, the 
ability of serum HBV RNA to predict the long-term outcome of NAs treatment remains 
unclear. Due to this fact, additional longitudinal studies are needed to assess the potential 
predictive role of serum HBV RNA in virological response. If it holds up, “virological response” 
can be redefined by complementing the current criteria with serum HBV RNA. Another study 
of 50 HBeAg-positive CHB patients treated with NAs reported that serum HBV flRNA levels at 
baseline can predict HBeAg seroconversion with superior accuracy to that of HBV DNA levels 
(AUROC=0.73 versus 0.67), and the decline of serum HBV RNA also showed a better 
prediction of HBeAg seroconversion than HBV DNA and HBsAg during antiviral treatment 
(32). This study indicates a quite good predictive value of serum HBV RNA for HBeAg 
seroconversion, which should be further validated in future studies with large sample size of 
HBeAg seroconverted patients.  
 
It has been reported that the effect of NAs and IFN-α treatment on serum HBV RNA is 
different (53). Mechanistically, while NAs specifically block the reverse transcription of 
encapsidated HBV pgRNA to DNA, the pleiotropic IFN-α can induce cccDNA degradation 
and inhibit cccDNA transcription (54), promote the decay of HBV pgRNA by 
interferon-stimulated ribonucleases (55), and prevent pgRNA encapsidation (56). Therefore, 
when compared to NAs treatment, IFN-α treatment is expected to achieve a stronger decline 
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of serum HBV RNA. Van Bömmel et al. reported that there was a greater reduction of serum 
HBV RNA in patients receiving PEGylated IFN-2a (peg-IFN) + LAM combination therapy 
compared to those receiving peg-IFN monotherapy (P<0.05) (34). However, to the best of our 
knowledge, no research has been done so far to compare the kinetics of serum HBV RNA 
decline between NAs monotherapy and IFN-α monotherapy. In addition, Jansen et al. found a 
more pronounced decline of HBV RNA load at week 30 in responders to peg-IFN and 
adefovir combination therapy than non-responders (P=0.01) (20). Regarding patients under 
peg-IFN therapy, van Bömmel et al. reported that the cutoff of serum HBV RNA at 5.5-log10 
copies/mL at week 12 can identify a higher proportion of non-responders (30%) than the HBV 
DNA cutoff of 8.9-log10 IU/mL (22%) or HBeAg cutoff of 2.7-log10 IU/mL (29%). However, the 
HBsAg cutoff of 2.8-log10 IU/mL could identify the largest proportion (41%) of non-responders 
(34). 
 
All these above-mentioned studies indicate that serum HBV RNA may serve as an 
additional biomarker for monitoring the efficacy of antiviral therapy. However, it remains 
unclear whether serum HBV RNA is better than current biomarkers, or whether it can replace 
other markers for such clinical applications. 
 
5.2. Serum HBV RNA and viral rebound after treatment cessation 
Currently, for HBeAg-positive patients being treated with NAs, treatment 
discontinuation can be considered after at least 1 year of consolidation therapy if patients 
achieve undetectable HBV DNA, ALT normalization and HBeAg seroconversion (57). Despite 
these criteria, virological relapse is common after treatment cessation. Therefore, better 
biomarker(s) for predicting safe withdrawal of NAs treatment in CHB patients is warranted. As 
serum HBV RNA is considered as a potential biomarker for cccDNA activity, the loss of 
serum HBV RNA may reflect the transcription silencing of cccDNA and may be an indicator 
for safe withdrawal of antiviral treatment (58, 59). In line with this notion, a study on 36 
patients treated with NAs showed that, after 3 months of treatment, serum HBV DNA+RNA 
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titers were tightly associated with HBV DNA rebound (P=0.043, OR 9.474, 95% CI 
(1.069–83.957)) and ALT relapse (P=0.050, OR 8.032, 95% CI 0.997–64.683) (40). However, 
the criteria for discontinuing NAs therapy in this study were not uniform. Another cohort study 
on 33 CHB patients withdrawing NAs revealed that viral rebound occurred in all patients with 
HBV RNA positive at the end of treatment, whereas, only in 25% of patients with HBV RNA 
negative (6). Theoretically, the most promising area for clinical application of serum HBV 
RNA is the prediction of relapse and sustained response, especially HBsAg loss after 
treatment discontinuation. However, additional studies with larger sample size are required to 
further evaluate the role of HBV RNA in predicting HBV relapse and sustained response after 
discontinuation of NAs treatment. 
 
6. FUTURE RESEARCH ON SERUM HBV RNA  
Before a widespread clinical applications of serum HBV RNA for CHB can be accepted 
and applied, certain fundamental questions need to be answered. 1) Basic and clinical 
studies are needed to further delineate the composition and molecular details of serum HBV 
RNA under different situations, such as different stages of CHB natural history, from baseline 
to different treatment time points, receiving NAs therapy or interferon therapy, as well as 
other new therapies for CHB. It is also essential to understand how the serum HBV RNA, 
specifically pgRNA, is released from hepatocytes. Is it in the virion or a naked capsid? Is the 
egress mechanism different between HBV DNA-containing particles and RNA-containing 
particles? 2) The methodology for detecting and quantifying serum HBV RNA, which may be 
related to the RNA species, as well as the intrahepatic cccDNA quantification, should be 
standardized to make the results of different studies comparable. Due to the potential high 
complexity of serum HBV RNA, an ideal PCR method would be expected to detect all 
possible serum HBV RNA species discussed in this review. 3) After characterizing serum 
HBV RNA species and perfecting the method for detection, their correlations with the clinical 
outcomes of CHB patients, including response to antiviral therapy especially HBsAg loss, 
hepatitis flare after withdrawal of NAs, need further investigation as different species of serum 
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HBV RNA may have different clinical implications. 4) The general applicability of serum HBV 
RNA among CHB patients of different ethnic groups and genotypes should be studied, and a 
pan-genotypic serum HBV RNA detection is warranted. 5) It has been reported that the 
circulating HBV RNA may be a marker for hepatocarcinogenesis (47, 49). Furthermore, a 
resent study demonstrated that pgRNA in liver tumor tissue correlated with the absence of 
tumorous microvascular invasion and better patient survival (60). Hence, the association and 
correlation of serum HBV RNA with HCC development also deserve exploration. 
 
7. CONCLUSION 
In summary, serum HBV RNA possess potentials to be a new marker for chronic hepatitis 
B virus infection. Growing evidence supports its correlations with serum HBsAg and HBcrAg 
and also with HBV DNA before treatment, and it may serve as a better surrogate marker for 
cccDNA activity in virally suppressed patients receiving NAs therapy. Although the 
methodologies of serum HBV RNA detection varied from study to study, it has shown 
preliminary clinical significance. Therefore, it is envisaged that extensive research will be 
conducted to further characterize the molecular biology of serum HBV RNA and assess its 
clinical potentials. 
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FIGURE LEGEND 
 
Figure 1. HBV life cycle. The major steps in HBV life cycle including entry, de-envelopment, 
cccDNA formation, mRNA transcription, protein translation, pgRNA encapsidation, DNA 
replication, viral particle assembly and secretion are shown. See text for details. 
(Abbreviations: NTCP: sodium taurocholate cotransporting polypeptide; rcDNA: relaxed 
circular DNA; cccDNA: covalently closed circular DNA; pgRNA: pregenomic RNA; ssDNA: 
single-stranded DNA; dslDNA: double-stranded linear DNA;  pol: polymerase; L: large 
surface protein; M: middle surface protein; S: small surface protein; HBsAg: hepatitis B 
surface antigen; HBeAg: hepatitis B e antigen; HBx: hepatitis B X protein; ER: endoplasmic 
reticulum; MVB: multivesicular body.) 
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Figure 2. Representatives of published PCR methods for detecting serum HBV RNA. 
HBV ORFs are shown as horizontal arrows and their nucleotide positions are marked on the 
scale bar which represents the length of HBV 3.5kb mRNA (genotype B/C). The blue and 
brown upward arrows pointing to scale bar indicate the location of canonical polyadenylation 
signal TATAAA and a cryptic polyadenylation signal CATAAA, respectively. The overlapping 
full-length HBV mRNAs are shown in wave lines. The direct repeat (DR) sequence DR1 and 
DR2 are denoted on pgRNA, the vertical red and black arrows pointing to pgRNA indicate the 
major 5’ splicing donor sites and 3’ splicing acceptor sites of pgRNA. The red lines 
underneath HBV mRNAs represent the PCR amplicon in the referenced studies (denoted 
with reference numbers in square brackets). Multiple PCR amplicons from the same 
reference are numbered. The primer information is provided in the embedded table, and 
additional information can be found in Table 1. “RT-Primer”, FW-Primer”, and “RV-Primer” 
refer to reverse transcription primer, forward primer and reverse primer of PCR, respectively. 
(Note: a The HBV-specific RT-primer in reference [6] is composed of a HBV-specific 
sequence and a unique anchored sequence at the 5’-end. The anchored sequence is used 
as RV-primer in PCR cycles. b RT-primer in reference [32] contains a 3’-terminal sequence 
complementary to the HBV flRNA or trRNA sequence adjacent to polyA tail,  a middle 
stretch of oligo(dT), and a 5’ artificial anchored sequence. The anchored sequence is same 
as RV-primer. c The sequences of RV-primers in reference [20], [21] , [36], [38] and [52] are 
identical to RT-primers.) 
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Table 1. Methods for quantifying serum HBV RNA 
Methods RT Primera Primer sites References 
RT-qPCR HBV specific 
primer 
X or C or S region [6], [20], [36], [37], [38], 
[43] ddPCRb HBV specific 
primer 
X or C region  21 , [38], [52] 
3’RACE-basedc 
qPCR 
Oligo(dT) primer poly A tail [32], [33], [34], [35] 
QuantiGene assaysd n/af n/af [42] 
Indirect 
quantificatione 
HBV specific 
primer 
PreC and C 
region 
[39], [40], [41] 
aThe primer for reverse transcription of serum HBV RNA into cDNA; bDroplet digital PCR; cA 
rapid amplification of complimentary DNA (cDNA)-ends (RACE)-based real-time polymerase 
chain reaction (PCR) technique; dQuantiGene Plex assays are hybridization-based and use 
branched DNA (bDNA) signal amplification technology; eSerum HBV RNA values equal to 
HBV nucleic acid determined by real-time RT-PCR minus HBV DNA determined by real-time 
PCR; f Information not available.  
 
 
Table 2. Correlation between serum HBV RNA and serum HBV DNA 
No. of 
subjects 
Correlation Refere
nces Before treatment              
P values 
      on treatment                    
P values 273 flRNA
a : r= 0.79 <0.05 n/ac n/ac [29] 
trRNAb：r= 0.14 <0.05 n/a
c n/ac 
62 flRNAa：r= 0.59 <0.001 3rd month: flRNA
a: 
r=0.53 
n/ac [32] 
 trRNA
b：r= 0.75 <0.001 trRNA
b: r=0.61 n/ac 
 
 
n/ac n/ac 6th month: flRNAa: 
r= 0.53 
n/ac 
 
 
n/ac n/ac trRNAb: r=0.62 n/ac 
 
52 n/ac n/ac C RNAd: 3rd month: 
R2= 0.321 
n/ac [41] 
86 PreC-C RNA
d: 
HBeAg(+):strongly 
n/ac n/ac n/ac [20] 
(-):strongly n/ac n/ac n/ac 
24 S RNAd: r=0.801 <0.001 S RNAd: 2nd month: 
r=0.837 
<0.001 [36] 
95 C RNA
d: HBeAg(+): 
R2=0.69 
<0.0001 n/ac n/ac [38] 
HBeAg(-): R2=0.62 <0.0001 n/ac n/ac 
102 C RNAd: r=0.928 <0.001 n/ac n/ac [52] 
84 C RNA
d: HBeAg(+): 
r= 0.532 
<0.001 n/ac n/ac [37] 
HBeAg(-): r= 0.741 <0.001 n/ac n/ac 
488 flRNA
a: HBeAg(+): 
r=0.72 
<0.001 n/ac n/ac [35] 
HBeAg(-): r=0.78 <0.001 n/ac n/ac 
102/16e X RNAd: R2=0.7756 n/ac X RNAd: R2=0.4963 n/ac [43] 
 
C RNAd: R2=0.8198 n/ac C RNAd: R2=0.5434 n/ac 
131 flRNAa: r=0.72 <0.05 n/ac n/ac [34] 
 
a flRNA refers to the HBV transcripts terminating at the canonical polyadenylation signal 
TATAAA motif downstream of HBx ORF; b trRNA refers to the HBV transcripts terminating at 
a cryptic polyadenylation signal, CATAAA, within the HBx ORF; c Information not available; d 
Primers for quantifying serum HBV RNA target at the X/PreC/C/S region of HBV genome; e 
102 untreated patients and 16 on-treatment patients. 
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Table 3. Correlation between serum HBV RNA and serum HBsAg 
 
No. of 
subjects 
Correlation  Referen
ces Before treatment            
P values 
 on treatment                
P values 47 n/ac n/ac C RNAd: >1 year: 
r=0.665 
<0.001 [21] 
62 flRNAa: r=0.4 n/ac 3rd month: flRNAa: 
r=0.39 
n/ac [32] 
 
trRNAb: r=0.37 n/ac           trRNAb: 
r=0.34 
n/ac 
 
n/ac n/ac 6th month: flRNAa: 
r=0.36 
n/ac 
n/ac n/ac           trRNAb: 
r=0.31 
n/ac 
52 n/ac n/ac C RNAd: 3rd month: 
R 2=0.407 
n/ac [41] 
86 PreC-C RNA
d: 
HBeAg(+):moderate  
n/ac n/ac n/ac [20] 
(-):no correlation  n/ac n/ac n/ac 
102 C RNAd: r=0.703 <0.0
01 
n/ac n/ac [52] 
84 C RNA
d: HBeAg(+): r= 
0.537 
<0.0
01 
n/ac n/ac [37] 
HBeAg(-): r=0.151 .50
3 
n/ac n/ac 
488 flRNA
a: HBeAg(+): r= 
0.54 
<0.0
01 
n/ac n/ac [35] 
HBeAg(-): r=0.19 .04 n/ac n/ac 
131 flRNAa: r=0.71 <0.0
5 
n/ac n/ac [34] 
 
a flRNA refers to the HBV transcripts terminating at the canonical polyadenylation signal 
TATAAA motif downstream of HBx ORF; b trRNA refers to the HBV transcripts terminating at 
a cryptic polyadenylation signal, CATAAA, within the HBX ORF; c Information not available. d 
Primers for quantifying serum HBV RNA target at the X/PreC/C/S region of HBV genome. 
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